Stockscreener 앱 받기
213.85
0.29%
-0.62
시간 외 거래:
213.85
전일 마감가:
$214.47
열려 있는:
$214.47
하루 거래량:
4.93M
Relative Volume:
0.91
시가총액:
$377.52B
수익:
$56.33B
순이익/손실:
$4.28B
주가수익비율:
89.10
EPS:
2.4
순현금흐름:
$17.83B
1주 성능:
+0.12%
1개월 성능:
+8.97%
6개월 성능:
+10.84%
1년 성능:
+19.81%
1일 변동 폭
$212.27
$215.18
1주일 범위
$208.28
$215.50
52주 변동 폭
$153.58
$218.66
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
ABBV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
213.85 | 377.52B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
80.98 | 359.47B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
JNJ
Johnson Johnson
|
164.25 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
94.72 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie CFO Scott Reents sells $3.75 million in stock - Investing.com
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
AbbVie upgraded to Buy at Erste Group on Friday - Yahoo Finance
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients - Benzinga
AbbVie’s Elahere demonstrates extended survival in Phase 3 MIRASOL trial - World Pharmaceutical Frontiers
Erste Group lifts AbbVie stock rating to Buy on growth forecast - Investing.com UK
AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer - Yahoo Finance
The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands - Yahoo Finance
AbbVie builds the case for ovarian cancer drug Elahere - pharmaphorum
AbbVie (NYSE:ABBV) Reports ELAHERE Success in Phase 3 Trials for Platinum-Resistant Ovarian Cancer - Yahoo Finance
AbbVie : Phase 3 Data Shows ELAHERE Cuts Death Risk By 32% In FRa-Positive PROC - Nasdaq
Top Analyst Reports for AbbVie, Lockheed Martin & Dell - Yahoo Finance
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk (NYSE:ABBV) - Seeking Alpha
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
GLP-1 Receptor Agonist Market Projected To Witness Substantial Growth, 2025-2032: Verrica Pharmaceuticals, - EIN News
DNA Repair Drugs Market May See a Big Move | Major Giants- AbbVie, AstraZeneca, AstraZeneca - openPR
AbbVie’s SWOT analysis: biopharmaceutical giant’s stock faces challenges and opportunities - Investing.com
Why AbbVie Inc. (ABBV) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Calls of the Day: United Airlines, Delta, IBM, Abbvie, Uber - CNBC
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
AbbVie: Hold Rating Maintained Amid Strong Skyrizi Sales and Valuation Concerns - TipRanks
Berenberg Adjusts Price Target on AbbVie to $195 From $165, Maintains Hold Rating -March 12, 2025 at 06:30 am EDT - Marketscreener.com
Abbvie, Dick's Sporting, Oracle - TradingView
(03/12/25) ABBV: A Higher-Yielding Healthcare Play That Continues to Shine - Moneyshow.com
11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey
Why AbbVie (ABBV) Dipped More Than Broader Market Today - Yahoo Finance
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
AbbVie at Leerink’s Global Healthcare Conference: Strategic Growth Path - Investing.com India
AbbVie at Leerink’s Global Healthcare Conference: Strategic Growth Path By Investing.com - Investing.com UK
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com
Xilio Lands Massive $2.1B AbbVie Partnership as Phase 2 Cancer Drug Shows Promise - StockTitan
AbbVie Inc. (ABBV): A Magnificent Dividend Growth Stock to Invest In - Insider Monkey
Rep. Jefferson Shreve Purchases Shares of AbbVie Inc. (NYSE:ABBV) - Defense World
Abbvie Says CEO Robert Michael's 2024 Total Compensation Was $18.5 Million -March 10, 2025 at 05:31 pm EDT - Marketscreener.com
Is AbbVie Inc. (ABBV) the Best Performing Dividend Stock to Buy Now? - Insider Monkey
Zacks Market Edge Highlights: Berkshire Hathaway, Aon plc and AbbVie - Zacks Investment Research
AbbVie Stock Hits All-Time High, Soars to $215.84 - Investing.com
Is AbbVie Stock Expensive At $215? - Forbes
Redburn Atlantic Adjusts Price Target on AbbVie to $234 From $216 -March 10, 2025 at 08:13 am EDT - Marketscreener.com
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy? - Yahoo Finance
Pfizer, Walmart, Super Micro, Salesforce, AbbVie: Insider Moves Unveiled! - TipRanks
AbbVie Inc. (ABBV): Among The Stocks With At Least $10 Million In Insider Sales Recently - Yahoo Finance
AbbVie Options Trading: A Deep Dive into Market Sentiment - Benzinga
Nanotechnology Drug Delivery Market to Witness Remarkable Growth with AbbVie Inc., Geistlich Pharma AG - openPR
Graves Disease Overactive Thyroid Market Deep Research - openPR
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More - Yahoo Finance
Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, Cynosure - Yahoo Finance
Rx Rundown: AbbVie, Jazz Pharmaceuticals, Sofinnova Partners and more - MM+M Online
This Insider Has Just Sold Shares In AbbVie - Simply Wall St
Wells Fargo & Company Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock - Defense World
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
0.07%
자본화:
|
볼륨(24시간):